Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
This radomized phase I/II trial is evaluating the efficacy of Ligilactobacillus salivarius PS2 (ingested daily 9 log10 colony-forming units) vs placebo on preventing mastitis in pregnant women (from approximately week 30 of pregnancy until delivery)
Primary Outcome Measures:
Evidence of clinical mastitis confirmed by microbiological cultures and somatic cell counts
The authors' conclusion was that oral administration of Ligilactobacillus salivarius PS2 during late pregnancy appears to be an efficient method of preventing infectious mastitis in a suscep…